News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
123,992 Results
Type
Article (7312)
Company Profile (59)
Press Release (116621)
Section
Business (38313)
Career Advice (88)
Deals (5943)
Drug Delivery (10)
Drug Development (23727)
Employer Resources (12)
FDA (3006)
Job Trends (3573)
News (68929)
Policy (4601)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (2)
2024 Pharm Country Standard (2)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (322)
Adcomms (10)
Allergies (3)
Alliances (11207)
ALS (8)
Alzheimer's disease (129)
Antibody-drug conjugate (ADC) (89)
Approvals (3038)
Artificial intelligence (76)
Autoimmune disease (3)
Automation (1)
Bankruptcy (55)
Best Places to Work (3305)
BIOSECURE Act (1)
Biosimilars (32)
Biotechnology (51)
Bladder cancer (49)
Brain cancer (21)
Breast cancer (176)
Cancer (1414)
Cardiovascular disease (15)
Career advice (75)
Career pathing (3)
CAR-T (65)
Cell therapy (148)
Cervical cancer (11)
Clinical research (19808)
Collaboration (300)
Compensation (87)
Complete response letters (1)
COVID-19 (313)
CRISPR (9)
C-suite (75)
Cystic fibrosis (1)
Data (668)
Decentralized trials (1)
Depression (4)
Diabetes (20)
Diagnostics (1305)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (40)
Drug pricing (10)
Drug shortages (1)
Duchenne muscular dystrophy (6)
Earnings (13021)
Editorial (8)
Employer branding (2)
Employer resources (13)
Events (23166)
Executive appointments (202)
FDA (3277)
Featured Employer (10)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (147)
Gene editing (17)
Generative AI (7)
Gene therapy (46)
GLP-1 (101)
Government (465)
Guidances (10)
Healthcare (4050)
Huntington's disease (2)
IgA nephropathy (4)
Immunology and inflammation (27)
Indications (12)
Infectious disease (332)
Inflammatory bowel disease (26)
Inflation Reduction Act (1)
Influenza (5)
Intellectual property (21)
Interviews (11)
IPO (2960)
IRA (7)
Job creations (483)
Job search strategy (69)
Kidney cancer (10)
Labor market (2)
Layoffs (122)
Leadership (2)
Legal (472)
Liver cancer (38)
Lung cancer (238)
Lymphoma (70)
Management (3)
Manufacturing (41)
MASH (5)
Medical device (843)
Medtech (843)
Mergers & acquisitions (3099)
Metabolic disorders (55)
Multiple sclerosis (7)
NASH (1)
Neurodegenerative disease (3)
Neuropsychiatric disorders (1)
Neuroscience (193)
NextGen: Class of 2025 (952)
Non-profit (493)
Northern California (723)
Now hiring (7)
Obesity (30)
Opinion (30)
Ovarian cancer (55)
Pain (5)
Pancreatic cancer (48)
Parkinson's disease (18)
Partnered (1)
Patents (33)
Patient recruitment (27)
Peanut (2)
People (12877)
Pharmaceutical (14)
Pharmacy benefit managers (1)
Phase I (7467)
Phase II (8344)
Phase III (6364)
Pipeline (340)
Podcasts (11)
Policy (14)
Postmarket research (472)
Preclinical (2321)
Press Release (2)
Prostate cancer (64)
Psychedelics (2)
Radiopharmaceuticals (162)
Rare diseases (54)
Real estate (733)
Recruiting (5)
Regulatory (4108)
Reports (8)
Research institute (661)
Resumes & cover letters (11)
RSV (8)
Schizophrenia (14)
Series A (33)
Series B (8)
Service/supplier (1)
Sickle cell disease (16)
Southern California (577)
Special edition (1)
Spinal muscular atrophy (16)
Sponsored (3)
Startups (752)
State (1)
Stomach cancer (9)
Supply chain (6)
The Weekly (11)
United States (5225)
Vaccines (116)
Venture capitalists (13)
Webinars (2)
Weight loss (15)
Women's health (1)
Date
Today (29)
Last 7 days (193)
Last 30 days (645)
Last 365 days (9086)
2025 (2016)
2024 (9472)
2023 (10639)
2022 (13112)
2021 (13176)
2020 (10961)
2019 (8592)
2018 (6333)
2017 (7122)
2016 (6284)
2015 (6949)
2014 (4524)
2013 (3091)
2012 (3341)
2011 (3329)
2010 (3038)
Location
Africa (83)
Alabama (19)
Alaska (1)
Arizona (14)
Arkansas (2)
Asia (10646)
Australia (1425)
California (1481)
Canada (390)
China (241)
Colorado (47)
Connecticut (66)
Delaware (91)
Europe (19556)
Florida (183)
Georgia (8)
Idaho (6)
Illinois (142)
India (7)
Indiana (44)
Iowa (1)
Japan (64)
Kansas (8)
Kentucky (9)
Maine (3)
Maryland (196)
Massachusetts (1255)
Michigan (15)
Minnesota (62)
Missouri (6)
Montana (5)
Nebraska (2)
Nevada (5)
New Hampshire (7)
New Jersey (406)
New Mexico (3)
New York (358)
North Carolina (162)
Northern California (723)
Ohio (40)
Oklahoma (1)
Oregon (5)
Pennsylvania (235)
Rhode Island (4)
South America (112)
South Carolina (2)
Southern California (577)
Tennessee (15)
Texas (252)
Utah (37)
Virginia (14)
Washington D.C. (5)
Washington State (145)
Wisconsin (11)
123,992 Results for "istari oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
Istari Oncology, Inc. today announced the first patient has been dosed via intravesicular instillation in the non-muscle-invasive bladder cancer (NMIBC) cohort of the LUMINOS-103 basket trial.
January 31, 2023
·
3 min read
Cancer
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.
March 3, 2025
·
7 min read
·
Heather McKenzie
Deals
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix Acquisition Corp. II worth $450 million in proceeds.
February 28, 2025
·
2 min read
·
Annalee Armstrong
BioCapital
Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)
Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)
November 9, 2021
·
4 min read
Press Releases
Advarra Unveils Oncology Research Pulse
March 12, 2025
·
3 min read
Bio NC
Istari Oncology to Participate in Upcoming Virtual Investor Conferences in September 2021
Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapies for the treatment of solid tumors, announced the company will participate in the following two virtual investment conferences taking place in September 2021:
September 7, 2021
·
1 min read
Bio NC
Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress
Istari Oncology today announced a poster presentation of new data from an enhanced dosing cohort within the LUMINOS-102 phase 2 clinical trial, which is assessing the safety and efficacy of lerapolturev (formerly PVSRIPO) alone or in combination with a programmed death receptor-1 (PD-1) inhibitor in patients with metastatic melanoma who have progressed on an anti-PD-1 containing regimen, and BRAF/MEK inhibitors if BRAF mutation positive.
October 18, 2022
·
5 min read
Bio NC
First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study
Istari Oncology, Inc. today announced its first patient was dosed in the company’s LUMINOS-103 bladder cancer sub-study (NCT04690699).
October 12, 2021
·
5 min read
Bladder cancer
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes
Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s approach makes use of an oncolytic immunotherapy that preferentially targets cancer cells and proliferates inside them, destroying them from the inside.
December 6, 2024
·
2 min read
·
Tristan Manalac
Business
Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team
Istari Oncology, Inc. today announced that Jamie Iudica has joined as Chief Manufacturing Officer (CMO).
June 8, 2021
·
2 min read
1 of 12,400
Next